Management Complexities of HIV/Hepatitis C Virus Coinfection in the Twenty-First Century

Clinics in Liver Disease

Volumn 12, Issue 3, 2008, Pages 587-609

  Lo Re III, Vincent ^a,b   Kostman, Jay R ^a   Amorosa, Valerianna K ^a,c  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Center for Clinical Epidemiology and Biostatistics   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DIDANOSINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOPOIETIC GROWTH FACTOR; HEPATITIS A VACCINE; HEPATITIS B VACCINE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; PEGINTERFERON; PROTEINASE INHIBITOR; RIBAVIRIN; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TIPRANAVIR; ZIDOVUDINE;

ALCOHOL ABUSE; ANEMIA; DISEASE COURSE; DRUG ABUSE; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INCIDENCE; INFECTION RISK; LACTIC ACIDOSIS; LEUKOPENIA; LIVER FIBROSIS; LIVER TOXICITY; MENTAL DISEASE; MIXED INFECTION; MORBIDITY; MORTALITY; PANCREATITIS; PREVALENCE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; COMORBIDITY; HEPATITIS C, CHRONIC; HIV; HUMANS; TREATMENT OUTCOME;

EID: 46749092918     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2008.03.009     Document Type: Review

References (144)

1. Sherman K.E., Rouster S.D., Chung R.T., et al. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 34 6 (2002) 831-837
2. Quan C.M., Krajden M., Grigoriew G.A., et al. Hepatitis C virus infection in patients infected with the human immunodeficiency virus. Clin Infect Dis 17 1 (1993) 117-119
3. Benhamou Y., Bochet M., Di Martino V., et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The multivirc group. Hepatology 30 4 (1999) 1054-1058
4. Graham C.S., Baden L.R., Yu E., et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 33 4 (2001) 562-569
5. Soto B., Sanchez-Quijano A., Rodrigo L., et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol 26 1 (1997) 1-5
6. Bica I., McGovern B., Dhar R., et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32 3 (2001) 492-497
7. Monga H.K., Rodriguez-Barradas M.C., Breaux K., et al. Hepatitis C virus infection-related morbidity and mortality among patients with human immunodeficiency virus infection. Clin Infect Dis 33 2 (2001) 240-247
8. Weber R., Sabin C.A., Friis-Moller N., et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 166 15 (2006) 1632-1641
9. Torriani F.J., Rodriguez-Torres M., Rockstroh J.K., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351 5 (2004) 438-450
10. Chung R.T., Andersen J., Volberding P., et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351 5 (2004) 451-459
11. Carrat F., Bani-Sadr F., Pol S., et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292 23 (2004) 2839-2848
12. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347 13 (2002) 975-982
13. Lissen E., Clumeck N., Sola R., et al. Histological response to pegIFNalpha-2a (40 KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 20 17 (2006) 2175-2181
14. Rodriguez-Torres M., Rodriguez-Orengo J.F., Rios-Bedoya C.F., et al. Effect of hepatitis C virus treatment in fibrosis progression rate (FPR) and time to cirrhosis (TTC) in patients co-infected with human immunodeficiency virus: a paired liver biopsy study. J Hepatol 46 4 (2007) 613-619
15. Hornberger J., Torriani F.J., Dieterich D.T., et al. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 36 4 (2006) 283-291
16. Saillour F., Dabis F., Dupon M., et al. Prevalence and determinants of antibodies to hepatitis C virus and markers for hepatitis B virus infection in patients with HIV infection in Aquitaine. Groupe d'epidemiologie clinique du SIDA en Aquitaine. BMJ 313 7055 (1996) 461-464
17. Ockenga J., Tillmann H.L., Trautwein C., et al. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J Hepatol 27 1 (1997) 18-24
18. Opravil M., Hunziker R., Luthy R., et al. Chronic hepatitis B and C in HIV-infected patients. Dtsch Med Wochenschr 123 24 (1998) 753-760 [in German]
19. Dimitrakopoulos A., Takou A., Haida A., et al. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J Infect 40 2 (2000) 127-131
20. Armstrong G.L., Wasley A., Simard E.P., et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144 10 (2006) 705-714
21. Eyster M.E., Diamondstone L.S., Lien J.M., et al. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: effect of coinfection with HIV virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol 6 6 (1993) 602-610
22. Makris M., Preston F.E., Rosendaal F.R., et al. The natural history of chronic hepatitis C in haemophiliacs. Br J Haematol 94 4 (1996) 746-752
23. Telfer P., Sabin C., Devereux H., et al. The progression of HCV-associated liver disease in a cohort of haemophilic patients. Br J Haematol 87 3 (1994) 555-561
24. Newell A., and Nelson M. Infectious hepatitis in HIV-seropositive patients. Int J STD AIDS 9 2 (1998) 63-69
25. Soriano V., Garcia-Samaniego J., Valencia E., et al. Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. Eur J Epidemiol 15 1 (1999) 1-4
26. Staples Jr. C.T., Rimland D., and Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (veterans affairs medical center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis 29 1 (1999) 150-154
27. Thomas D.L., Vlahov D., Solomon L., et al. Correlates of hepatitis C virus infections among injection drug users. Medicine (Baltimore) 74 4 (1995) 212-220
28. Schreiber G.B., Busch M.P., Kleinman S.H., et al. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med 334 26 (1996) 1685-1690
29. Ghosn J., Pierre-Francois S., Thibault V., et al. Acute hepatitis C in HIV-infected men who have sex with men. HIV Med 5 4 (2004) 303-306
30. Pappalardo B.L. Influence of maternal human immunodeficiency virus (HIV) co-infection on vertical transmission of hepatitis C virus (HCV): a meta-analysis. Int J Epidemiol 32 5 (2003) 727-734
31. Gibb D.M., Goodall R.L., Dunn D.T., et al. Mother-to-child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet 356 9233 (2000) 904-907
32. Thomas D.L., Villano S.A., Riester K.A., et al. Perinatal transmission of hepatitis C virus from human immunodeficiency virus type 1-infected mothers. Women and Infants Transmission Study. J Infect Dis 177 6 (1998) 1480-1488
33. Zanetti A.R., Tanzi E., Paccagnini S., et al. Mother-to-infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet 345 8945 (1995) 289-291
34. Alter M.J., Margolis H.S., Krawczynski K., et al. The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. N Engl J Med 327 27 (1992) 1899-1905
35. Thomas D.L., Astemborski J., Rai R.M., et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 284 4 (2000) 450-456
36. Villano S.A., Vlahov D., Nelson K.E., et al. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29 3 (1999) 908-914
37. Di Martino V., Rufat P., Boyer N., et al. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 34 6 (2001) 1193-1199
38. Eyster M.E., Fried M.W., Di Bisceglie A.M., et al. Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 84 4 (1994) 1020-1023
39. Marcellin P., Martinot-Peignoux M., Elias A., et al. Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay. J Infect Dis 170 2 (1994) 433-435
40. Serfaty L., Costagliola D., Wendum D., et al. Impact of early-untreated HIV infection on chronic hepatitis C in intravenous drug users: a case-control study. AIDS 15 15 (2001) 2011-2016
41. Garcia-Samaniego J., Soriano V., Castilla J., et al. Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. Am J Gastroenterol 92 7 (1997) 1130-1134
42. Pol S., Trinh Thi N., Thiers V., et al. Influence of HIV infection on chronic hepatitis C in drug users. J Hepatol 23 Suppl 1 (1995) 96
43. Romeo R., Rumi M.G., Donato M.F., et al. Hepatitis C is more severe in drug users with human immunodeficiency virus infection. J Viral Hepat 7 4 (2000) 297-301
44. Fuster D., Planas R., Muga R., et al. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy. AIDS Res Hum Retroviruses 20 12 (2004) 1293-1297
45. Sulkowski MS, Mehta S, Torbenson M, et al. Unexpected significant liver disease among HIV/HCV-coinfected persons with minimal fibrosis on initial liver biopsy. Presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22-25, 2005 [Abstract 121].
46. Giordano T.P., Kramer J.R., Souchek J., et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992-2001. Arch Intern Med 164 21 (2004) 2349-2354
47. Kramer J.R., Giordano T.P., Souchek J., et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 100 1 (2005) 56-63
48. Garcia-Samaniego J., Rodriguez M., Berenguer J., et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 96 1 (2001) 179-183
49. Puoti M., Bruno R., Soriano V., et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS 18 17 (2004) 2285-2293
50. Lesens O., Deschenes M., Steben M., et al. Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection. J Infect Dis 179 5 (1999) 1254-1258
51. Ragni M.V., and Belle S.H. Impact of human immunodeficiency virus infection on progression to end-stage liver disease in individuals with hemophilia and hepatitis C virus infection. J Infect Dis 183 7 (2001) 1112-1115
52. Posthouwer D., Makris M., Yee T.T., et al. Progression to end-stage liver disease in patients with inherited bleeding disorders and hepatitis C: an international, multicenter cohort study. Blood 109 9 (2007) 3667-3671
53. Pineda J.A., Romero-Gomez M., Diaz-Garcia F., et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 41 4 (2005) 779-789
54. Merchante N., Giron-Gonzalez J.A., Gonzalez-Serrano M., et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20 1 (2006) 49-57
55. Martin-Carbonero L., Soriano V., Valencia E., et al. Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses 17 16 (2001) 1467-1471
56. Puoti M., Spinetti A., Ghezzi A., et al. Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 24 3 (2000) 211-217
57. Rockstroh J.K., Spengler U., Sudhop T., et al. Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. Am J Gastroenterol 91 12 (1996) 2563-2568
58. Rosenthal E., Poiree M., Pradier C., et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS 17 12 (2003) 1803-1809
59. Tedaldi E, Puoti M, Neuhaus J, et al. Opportunistic disease and mortality in patients co-infected with hepatitis C virus (HCV) and/or hepatitis B virus (HBV) in the SMART (Strategic Management of Antiretroviral Therapy) study. Presented at the 4th International AIDS Society Conference. Sydney, Australia. July 22-25, 2007 [Abstract TUAB203].
60. Mehta S.H., Thomas D.L., Torbenson M., et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 41 1 (2005) 123-131
61. Brau N., Salvatore M., Rios-Bedoya C.F., et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 44 1 (2006) 47-55
62. Verma S., Wang C.H., Govindarajan S., et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients?. Clin Infect Dis 42 2 (2006) 262-270
63. Benhamou Y., Di Martino V., Bochet M., et al. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 34 2 (2001) 283-287
64. Qurishi N., Kreuzberg C., Luchters G., et al. Effect of antiretroviral therapy on liver-related mortality in patients with HIV and hepatitis C virus coinfection. Lancet 362 9397 (2003) 1708-1713
65. Nunez M. Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. J Hepatol 44 Suppl 1 (2006) S132-S139
66. AIDS Clinical Trials Group. Table of grading severity of adult adverse experiences (1996), Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville (MD)
67. Sulkowski M.S., Thomas D.L., Chaisson R.E., et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 283 1 (2000) 74-80
68. Aceti A., Pasquazzi C., Zechini B., et al. Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV: the role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 29 1 (2002) 41-48
69. Bonfanti P., Landonio S., Ricci E., et al. Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27 3 (2001) 316-318
70. den Brinker M., Wit F.W., Wertheim-van Dillen P.M., et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 14 18 (2000) 2895-2902
71. Nunez M., Lana R., Mendoza J.L., et al. Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 27 5 (2001) 426-431
72. Rodriguez-Rosado R., Garcia-Samaniego J., and Soriano V. Hepatotoxicity after introduction of highly active antiretroviral therapy [letter]. AIDS 12 10 (1998) 1256
73. Saves M., Raffi F., Clevenbergh P., et al. Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in human immunodeficiency virus-infected patients. The APROCO Study Group. Antimicrob Agents Chemother 44 12 (2000) 3451-3455
74. Saves M., Vandentorren S., Daucourt V., et al. Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine cohort, France, 1996-1998. Groupe d'epidemiologie clinique de sida en Aquitaine (GECSA). AIDS 13 17 (1999) F115-F121
75. Wit F.W., Weverling G.J., Weel J., et al. Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 186 1 (2002) 23-31
76. Melvin D.C., Lee J.K., Belsey E., et al. The impact of co-infection with hepatitis C virus and HIV on the tolerability of antiretroviral therapy. AIDS 14 4 (2000) 463-465
77. Aranzabal L., Casado J.L., Moya J., et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 40 4 (2005) 588-593
78. Labarga P., Soriano V., Vispo M.E., et al. Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. J Infect Dis 196 5 (2007) 670-676
79. Sulkowski M.S., Mehta S.H., Torbenson M., et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 19 6 (2005) 585-592
80. Gonzalez de Requena D., Nunez M., Jimenez-Nacher I., et al. Liver toxicity caused by nevirapine. AIDS 16 2 (2002) 290-291
81. Martinez E., Blanco J.L., Arnaiz J.A., et al. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15 10 (2001) 1261-1268
82. Macias J., Castellano V., Merchante N., et al. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine. AIDS 18 5 (2004) 767-774
83. Sulkowski M.S., Mehta S.H., Chaisson R.E., et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18 17 (2004) 2277-2284
84. Rockstroh J, Sulkowski M, Neubacher D, et al. 24-Week efficacy of tipranavir boosted with ritonavir in hepatitis B- or C-coinfected patients. Presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. December 16-19, 2006 [Abstract H-525].
85. Pineda J.A., Palacios R., Rivero A., et al. Low incidence of severe liver toxicity in patients receiving antiretroviral combinations including atazanavir. J Antimicrob Chemother 57 5 (2006) 1016-1017
86. Zucker S.D., Qin X., Rouster S.D., et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 98 22 (2001) 12671-12676
87. Cooper C.L., Parbhakar M.A., and Angel J.B. Hepatotoxicity associated with antiretroviral therapy containing dual versus single protease inhibitors in individuals coinfected with hepatitis C virus and human immunodeficiency virus. Clin Infect Dis 34 9 (2002) 1259-1263
88. Clanon K.A., Johannes Mueller J., and Harank M. Integrating treatment for hepatitis C virus infection into an HIV clinic. Clin Infect Dis 40 Suppl 5 (2005) S362-S366
89. Pol S., Lamorthe B., Thi N.T., et al. Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users. J Hepatol 28 6 (1998) 945-950
90. Peters M.G., and Terrault N.A. Alcohol use and hepatitis C. Hepatology 36 5 Suppl 1 (2002) S220-S225
91. National Institutes of Health consensus development conference statement: management of hepatitis C: June 10-12, 2002. Hepatology 36 5 Suppl 1 (2002) S3-S20
92. Alberti A., Clumeck N., Collins S., et al. Short statement of the first European consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. J Hepatol 42 5 (2005) 615-624
93. Tien P.C. Management and treatment of hepatitis C virus infection in HIV-infected adults: recommendations from the veterans Affairs Hepatitis C Resource Center Program and National Hepatitis C Program office. Am J Gastroenterol 100 10 (2005) 2338-2354
94. Clifford D.B., Evans S.R., Yang Y., et al. The neuropsychological and neurological impact of hepatitis C virus co-infection in HIV-infected subjects. AIDS 19 Suppl 3 (2005) S64-S71
95. Zarski J.P., Bohn B., Bastie A., et al. Characteristics of patients with dual infection by hepatitis B and C viruses. J Hepatol 28 1 (1998) 27-33
96. Vento S., Garofano T., Renzini C., et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 338 5 (1998) 286-290
97. Lemon S.M., and Thomas D.L. Vaccines to prevent viral hepatitis. N Engl J Med 336 3 (1997) 196-204
98. Ghany M.G., Kleiner D.E., Alter H., et al. Progression of fibrosis in chronic hepatitis C. Gastroenterology 124 1 (2003) 97-104
99. Goedert J.J., Hatzakis A., Sherman K.E., et al. Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfection. J Infect Dis 184 9 (2001) 1202-1205
100. Sanchez-Conde M., Berenguer J., Miralles P., et al. Liver biopsy findings for HIV-infected patients with chronic hepatitis C and persistently normal levels of alanine aminotransferase. Clin Infect Dis 43 5 (2006) 640-644
101. Bravo A.A., Sheth S.G., and Chopra S. Liver biopsy. N Engl J Med 344 7 (2001) 495-500
102. Bedossa P., Dargere D., and Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 38 6 (2003) 1449-1457
103. Poynard T., Mathurin P., Lai C.L., et al. A comparison of fibrosis progression in chronic liver diseases. J Hepatol 38 3 (2003) 257-265
104. Wong J.B., and Koff R.S. Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis. Ann Intern Med 133 9 (2000) 665-675
105. Macias J., Giron-Gonzalez J.A., Gonzalez-Serrano M., et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple non-invasive indexes. Gut 55 3 (2006) 409-414
106. Al-Mohri H., Cooper C., Murphy T., et al. Validation of a simple model for predicting liver fibrosis in HIV/hepatitis C virus-coinfected patients. HIV Med 6 6 (2005) 375-378
107. Kelleher T.B., Mehta S.H., Bhaskar R., et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 43 1 (2005) 78-84
108. Myers R.P., Benhamou Y., Imbert-Bismut F., et al. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus co-infected patients. AIDS 17 5 (2003) 721-725
109. Sterling R.K., Lissen E., Clumeck N., et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 43 6 (2006) 1317-1325
110. Castera L., Vergniol J., Foucher J., et al. Prospective comparison of transient elastography, FbroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 128 2 (2005) 343-350
111. Ziol M., Handra-Luca A., Kettaneh A., et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41 1 (2005) 48-54
112. Soriano V., Puoti M., Sulkowski M., et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV international panel. AIDS 21 9 (2007) 1073-1089
113. Soriano V. Treatment of chronic hepatitis C in HIV-positive individuals: selection of candidates. J Hepatol 44 Suppl 1 (2006) S44-S48
114. Pineda J.A., Garcia-Garcia J.A., Aguilar-Guisado M., et al. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 46 3 (2007) 622-630
115. De Bona A, Galli L, Gallotta G, et al. Rate of cirrhosis progression reduced in HIV/HCV co-infected non-responders to anti-HCV therapy. Presented at the 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention. Syndney, Australia, July 22-25, 2007.
116. Dore G.J., Torriani F.J., Rodriguez-Torres M., et al. Baseline factors prognostic of sustained virological response in patients with HIV-hepatitis C virus co-infection. AIDS 21 12 (2007) 1555-1559
117. Fuster D., Planas R., Gonzalez J., et al. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response. Antivir Ther 11 4 (2006) 473-482
118. Ramos B., Nunez M., Rendon A., et al. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. J Viral Hepat 14 6 (2007) 387-391
119. Soriano V., Miralles C., Berdun M.A., et al. Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther 12 4 (2007) 469-476
120. Shire N.J., and Sherman K.E. Clinical trials of treatment for hepatitis C virus infection in HIV-infected patients: past, present, and future. Clin Infect Dis 41 Suppl 1 (2005) S63-S68
121. Sherman K, Andersen J, Butt AA, et al. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV-co-infected patients: early viral response and effect on fibrosis in treated and control subjects. Presented at the 15th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 3-6, 2008 [Abstract 59].
122. Harrison S.A. Small molecule and novel treatments for chronic hepatitis C virus infection. Am J Gastroenterol 102 10 (2007) 2332-2338
123. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358 9286 (2001) 958-965
124. Cooper C.L., Al-Bedwawi S., Lee C., et al. Rate of infectious complications during interferon-based therapy for hepatitis C is not related to neutropenia. Clin Infect Dis 42 12 (2006) 1674-1678
125. Lo Re III V., and Kostman J.R. Anemia during treatment of hepatitis C in HIV-infected patients. AIDS Read 14 10 (2004) 555-557 562, 565-71
126. Peck-Radosavljevic M., Wichlas M., Homoncik-Kraml M., et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 123 1 (2002) 141-151
127. Bodenheimer Jr. H.C., Lindsay K.L., Davis G.L., et al. Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial. Hepatology 26 2 (1997) 473-477
128. De Franceschi L., Fattovich G., Turrini F., et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 31 4 (2000) 997-1004
129. Sulkowski M.S., Dieterich D.T., Bini E.J., et al. Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial. J Acquir Immune Defic Syndr 39 4 (2005) 504-506
130. Behler C.M., Vittinghoff E., Lin F., et al. Hematologic toxicity associated with interferon-based hepatitis C therapy in HIV type 1-coinfected subjects. Clin Infect Dis 44 10 (2007) 1375-1383
131. Lo Re III V., Kostman J.R., Gross R., et al. Incidence and risk factors for weight loss during dual HIV/hepatitis C virus therapy. J Acquir Immune Defic Syndr 44 3 (2007) 344-350
132. Alvarez D., Dieterich D.T., Brau N., et al. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 13 10 (2006) 683-689
133. Kakuda T.N., and Brinkman K. Mitochondrial toxic effects and ribavirin. Lancet 357 9270 (2001) 1802-1803
134. Butt A.A. Fatal lactic acidosis and pancreatitis associated with ribavirin and didanosine therapy. AIDS Read 13 7 (2003) 344-348
135. Guyader D., Poinsignon Y., Cano Y., et al. Fatal lactic acidosis in a HIV-positive patient treated with interferon and ribavirin for chronic hepatitis C. J Hepatol 37 2 (2002) 289-291
136. Lafeuillade A., Hittinger G., and Chadapaud S. Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 357 9252 (2001) 280-281
137. Salmon-Ceron D., Chauvelot-Moachon L., Abad S., et al. Mitochondrial toxic effects and ribavirin. Lancet 357 9270 (2001) 1803-1804
138. Bani-Sadr F., Carrat F., Rosenthal E., et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 41 12 (2005) 1806-1809
139. Mauss S., Valenti W., DePamphilis J., et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 18 13 (2004) F21-F25
140. Bani-Sadr F., Denoeud L., Morand P., et al. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role?. J Acquir Immune Defic Syndr 45 1 (2007) 123-125
141. Vispo E, Barriero P, Maida I, et al. Abacavir-containing HAART reduces the chances for sustained virological response to pegylated-interferon plus ribavirin in HIV-infected patients with chronic hepatitis C. Presented at the Third International Workshop on HIV and Hepatitis Coinfection. Paris, France, June 7-9, 2007 [Abstract 46].
142. Barreiro P., Rodriguez-Novoa S., Labarga P., et al. Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. J Infect Dis 195 7 (2007) 973-979
143. Miro J.M., Aguero F., Laguno M., et al. Liver transplantation in HIV/hepatitis co-infection. J HIV Ther 12 1 (2007) 24-35
144. de Vera M.E., Dvorchik I., Tom K., et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 6 12 (2006) 2983-2993